Category: Pharmaceuticals
Global Pharmaceuticals
-
Cannabis Edibles
... CAGR of 22.0% over the analysis period 2024-2030. Solid Cannabis Edibles, one of the segments analyzed in the report, is expected to record a 22.2% CAGR and reach US$38.2 Billion by the end of the ... Read More
-
Cancer Supportive Care
... at a CAGR of 2.2% over the analysis period 2024-2030. Opioids, one of the segments analyzed in the report, is expected to record a 2.3% CAGR and reach US$11.1 Billion by the end of the ... Read More
-
Penile Implants
... CAGR of 4.3% over the analysis period 2024-2030. Inflatable Implant, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$557.9 Million by the end of the analysis ... Read More
-
Swine Health
... CAGR of 5.8% over the analysis period 2024-2030. Antibiotics, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$2.5 Billion by the end of the analysis period. ... Read More
-
Influenza Diagnostics
... CAGR of 5.2% over the analysis period 2024-2030. RIDT Test, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$2.0 Billion by the end of the analysis ... Read More
-
Psychiatric and Substance Abuse Hospitals
... Billion by 2030, growing at a CAGR of 4.7% over the analysis period 2024-2030. Alcoholism Rehabilitation Hospitals, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$13.5 ... Read More
-
Oral Solid Dosage Forms (OSDF) and Pharma Excipients
... 2024, is expected to reach US$1.8 Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. Polymers, one of the segments analyzed in the report, is expected to record a 6.2% ... Read More
-
Spectator Sports
... CAGR of 5.8% over the analysis period 2024-2030. Sports Team and Clubs, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$284.6 Billion by the end of ... Read More
-
Automotive Micro Switch
... at a CAGR of 3.9% over the analysis period 2024-2030. Standard Micro Switches, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$922.8 Million by the end ... Read More
-
Extracorporeal CO2 Removal Devices
... 2030, growing at a CAGR of 6.0% over the analysis period 2024-2030. Extracorporeal CO2 Machines, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$89.9 Million by ... Read More
-
Flea and Tick Products
... 2030, growing at a CAGR of 7.9% over the analysis period 2024-2030. Chewable Products, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$7.3 Billion by the ... Read More
-
Implantable Drug Delivery Devices
... 2030, growing at a CAGR of 6.1% over the analysis period 2024-2030. Contraceptive Implants, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$9.8 Billion by the ... Read More
-
Venturi Masks
... CAGR of 11.5% over the analysis period 2024-2030. COPD Application, one of the segments analyzed in the report, is expected to record a 13.5% CAGR and reach US$2.9 Billion by the end of the analysis ... Read More
-
Tangential Flow Filtration
... at a CAGR of 12.0% over the analysis period 2024-2030. Single-Use Systems, one of the segments analyzed in the report, is expected to record a 13.3% CAGR and reach US$2.0 Billion by the end of ... Read More
-
Breast Cancer Therapeutics
... at a CAGR of 12.3% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 12.6% CAGR and reach US$74.9 Billion by the end of ... Read More
-
Colorectal Cancer Therapeutics
... at a CAGR of 6.5% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$14.9 Billion by the end of ... Read More
-
Zika Virus Testing
... at a CAGR of 5.8% over the analysis period 2024-2030. Molecular Testing, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$192.4 Million by the end of ... Read More
-
Brachytherapy
... 4.3% over the analysis period 2024-2030. High Dose Rate Brachytherapy, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$1.6 Billion by the end of the analysis ... Read More
-
Antimicrobial Coatings
... CAGR of 8.1% over the analysis period 2024-2030. Silver Coatings, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$8.3 Billion by the end of the analysis ... Read More
-
Insulin Pens
... CAGR of 7.2% over the analysis period 2024-2030. Disposable Insulin Pens, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$11.6 Billion by the end of the ... Read More
-
Soft Tissue Allografts
... at a CAGR of 4.9% over the analysis period 2024-2030. Orthopedic Application, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$2.9 Billion by the end of ... Read More
-
Animal Proteins
... CAGR of 6.9% over the analysis period 2024-2030. Food & Beverage Application, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$1.6 Billion by the end of ... Read More
-
Sports Management Software
... at a CAGR of 13.2% over the analysis period 2024-2030. Cloud Deployment, one of the segments analyzed in the report, is expected to record a 14.0% CAGR and reach US$8.2 Billion by the end of ... Read More
-
Cerium Oxide Nanoparticles
... at a CAGR of 18.7% over the analysis period 2024-2030. Dispersion Form, one of the segments analyzed in the report, is expected to record a 19.6% CAGR and reach US$2.2 Billion by the end of ... Read More
-
Chainsaws
... 3.9% over the analysis period 2024-2030. Fuel-Operated Chainsaws, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$3.8 Billion by the end of the analysis period. Growth ... Read More